Artrya (ASX:AYA) Shares Slide 14% on Quarterly Update

Aditi Sarkar

30 July 2026 09:33 PM AEST

Artrya (ASX:AYA) Shares Slide 14% on Quarterly Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Artrya Limited (ASX:AYA) tumbled 14.47% to $4.08 on 30 July 2026, a day after a quarterly operational update, as investors weighed a still-pending US regulatory decision against the AI heart-imaging company's ongoing cash burn.
Shares in Artrya Limited (ASX:AYA), the Australian developer of artificial-intelligence software that reads coronary CT scans, fell heavily on Thursday, 30 July 2026.
The broader S&P/ASX 200 slipped 0.92% as gold miners were sold off, yet Information Technology was the only sector to finish higher, up 0.84%.
The fall arrived a day after Artrya released a business update, dated 29 July 2026, covering the June 2026 quarter.

Artrya Limited (ASX:AYA) tumbled 14.47% to $4.08 on 30 July 2026, a day after a quarterly operational update, as investors weighed a still-pending US regulatory decision against the AI heart-imaging company's ongoing cash burn.

Company Overview

The fall arrived a day after Artrya released a business update, dated 29 July 2026, covering the June 2026 quarter. On its face the announcement read positively: the company confirmed a second revenue-generating customer had gone live and said it had submitted a further US regulatory application. Yet the reaction was sharply negative, suggesting the market had been positioned for more.

Recent Developments

Artrya reported a pro forma cash position of $74.0 million as at 30 June 2026, a substantial balance that reflects the roughly $75 million in fresh funding it previously raised to support its US commercialisation push.

What May Be Watched Next

The most obvious near-term catalyst is a decision on the Coronary Flow 510(k) application. Clearance within the targeted second-half window, followed by a commercial launch, would broaden Artrya's offering and its reimbursement footprint. Successful conversion of its three foundation customers into scaled, recurring revenue would also help validate the model, as would progress under the SAPPHIRE study. Additional agreements with US hospital systems, and evidence that scan volumes and subscription…

Key Risks

The risks are considerable and help explain why sentiment can shift quickly. Artrya remains effectively pre-revenue at scale and is consuming cash at a meaningful rate, so execution on US commercialisation is central to the investment case. Any delay in converting customers, slower-than-expected scan volumes, or a shortfall in recurring revenue could extend the path to break-even and pressure the cash runway.

What does Artrya (ASX do?

What is the latest development?

What financial or operational point stands out?

What may be watched next?

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.